Načítá se...
Use of broadly neutralizing antibodies for HIV-1 prevention
Antibodies have a long history in antiviral therapy, but until recently they have not been actively pursued for HIV-1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmountable technical, financial, and logistical hurdles. Recent advances in the identi...
Uloženo v:
| Vydáno v: | Immunol Rev |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5314445/ https://ncbi.nlm.nih.gov/pubmed/28133803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12511 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|